ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 57 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,513 | -82.0% | 3,863 | -67.8% | 0.00% | -75.0% |
| Q2 2023 | $114,274 | +393948.3% | 11,991 | +357.0% | 0.00% | +300.0% |
| Q1 2023 | $29 | -77.9% | 2,624 | -70.4% | 0.00% | -80.0% |
| Q4 2022 | $131 | -99.8% | 8,865 | +213.3% | 0.01% | +400.0% |
| Q3 2022 | $54,000 | -78.7% | 2,830 | -76.2% | 0.00% | -83.3% |
| Q2 2022 | $253,000 | +1481.2% | 11,877 | +1282.7% | 0.01% | – |
| Q1 2022 | $16,000 | -57.9% | 859 | -52.3% | 0.00% | -100.0% |
| Q4 2021 | $38,000 | +65.2% | 1,799 | +80.6% | 0.00% | 0.0% |
| Q3 2021 | $23,000 | -70.5% | 996 | -65.1% | 0.00% | -50.0% |
| Q2 2021 | $78,000 | +116.7% | 2,856 | +132.4% | 0.00% | +100.0% |
| Q1 2021 | $36,000 | +227.3% | 1,229 | +223.4% | 0.00% | – |
| Q4 2020 | $11,000 | -96.7% | 380 | -96.6% | 0.00% | -100.0% |
| Q3 2020 | $332,000 | +591.7% | 11,340 | +615.9% | 0.00% | +100.0% |
| Q2 2020 | $48,000 | +26.3% | 1,584 | +25.5% | 0.00% | 0.0% |
| Q1 2020 | $38,000 | – | 1,262 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |